ストックスクリーナーアプリを入手
4.19
0.24%
0.01
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Point72 DIFC Ltd Acquires Shares of 2,848 Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Commonwealth Equity Services LLC Invests $303,000 in Diebold Nixdorf, Incorporated (NYSE:DBD) - Defense World
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Domino’s Pizza, Inc. (NYSE:DPZ) Position Lowered by Epoch Investment Partners Inc. - Defense World
Victory Capital Management Inc. Sells 10,924 Shares of Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Dolby Laboratories, Inc. (NYSE:DLB) Shares Sold by Federated Hermes Inc. - Defense World
Deftones’ Album Rises To A New Peak–Nearly 20 Years After Its Release - Forbes
Deutsche Telekom downgraded to Neutral from Outperform at Oddo BHF - TipRanks
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week - Simply Wall St
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7% - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 2.7% - MarketBeat
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com India
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com UK
DiaMedica Therapeutics Upcoming Conference Participation - Business Wire
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com
DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com India
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc. - Defense World
Vanguard Group Inc. Acquires 211,351 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - MarketBeat
Oppenheimer Reiterates “Outperform” Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics' (DMAC) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July - Defense World
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 - Investing.com
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 - Investing.com India
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 By Investing.com - Investing.com Canada
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript - Seeking Alpha
DiaMedica Therapeutics (NASDAQ:DMAC) Releases Earnings Results - MarketBeat
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Business Wire
DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday - Defense World
DiaMedica Therapeutics (DMAC) Scheduled to Post Earnings on Wednesday - MarketBeat
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? - Yahoo Finance
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 10.8% in July - MarketBeat
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 10.8% - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 22.1% in June - MarketBeat
Chronic Kidney Disease FDA Approvals, Emerging Drugs, - openPR
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) 12% gain last week benefited both retail investors who own 45% as well as insiders - Simply Wall St
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point - Seeking Alpha
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39% - Yahoo Finance
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Koch Thomas Von Acquires 1,200,000 Shares of Stock - Defense World
RA Capital Management buys $49.95m of Eliem Therapeutics stock By Investing.com - Investing.com Canada
Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Buys 1,200,000 Shares of Stock - MarketBeat
Swedish Match seeks FDA nod for wider snus marketing By Investing.com - Investing.com
DiaMedica Therapeutics insider buys $3m in company shares By Investing.com - Investing.com UK
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement - Business Wire
Analyzing the Impact of Earnings Reports on DiaMedica Therapeutics Inc Inc. (DMAC) Price Performance - The InvestChronicle
Indie semiconductor president sells $307,000 in company stock By Investing.com - Investing.com Canada
DiaMedica secures $11.8 million in private placement By Investing.com - Investing.com Australia
DiaMedica secures $11.8 million in private placement By Investing.com - Investing.com India
Joby Aviation CFO sells $29,281 in company stock By Investing.com - Investing.com
DiaMedica secures $11.8 million in private placement By Investing.com - Investing.com UK
Strategic Announcements Propel DiaMedica (DMAC) Stock Surge - Stocks Telegraph
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Shares Rise 12% After $12M Private Placement - MarketWatch
Diamedica Therapeutics Expands Trials to Address Preeclampsia - TipRanks
DiaMedica Therapeutics Announces $11.8 Million Private Placement - Business Wire
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia - StockTitan
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):